- Home
- BZFD vs SERA Comparison
BZFD vs SERA Comparison
Compare BZFD & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BZFD | SERA |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 75.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BZFD | SERA |
|---|---|---|
| Price | $0.46 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 370.3K | 31.9K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,266,000.00 | $81,000.00 |
| Revenue This Year | N/A | $270.37 |
| Revenue Next Year | $108.07 | $611.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.46 | $1.56 |
| 52 Week High | $2.21 | $3.85 |
Technical Indicators
Market Signals| Indicator | BZFD | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 19.54 | 45.49 |
| Support Level | N/A | $1.97 |
| Resistance Level | $0.83 | $2.07 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 1.60 | 20.69 |
Price Performance
Historical ComparisonAbout BZFD BuzzFeed Inc.
BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.